Dados do Trabalho

Título

Antibiofilm activity of tobramycin encapsulated in zein nanoparticles against resistant Klebsiella pneumoniae strains

Introdução

Biofilms are constantly associated with infections in humans, especially digestive, urinary, and respiratory tract infections induced mainly by catheters and other invasive devices. Among the pathogens, antimicrobial-resistant strains of Klebsiella pneumoniae stand out. The ability of this bacteria to produce biofilm is associated with poor penetration of antibiotics in the biofilm matrix, therapeutic failure, increased resistance, leading to infections that cause increased morbimortality and reduced quality of life for patients. In this sense, there is a need to develop therapeutic strategies to inhibit and/or eradicate biofilms produced by resistant K. pneumoniae. Thus, the encapsulation of antimicrobial in zein nanoparticles becomes a promising alternative in the use of oral particles to treat infections caused by resistant and biofilm-producing K. pneumoniae. 

Objetivo (s)

Thus, this study aimed to evaluate the antibiofilm activity of tobramycin encapsulated in zein nanoparticles (TOB-ZNP). 

Material e Métodos

The TOB-ZNP were prepared by the method of nanoprecipitation and characterized by measuring the particle size (Ø), polydispersity index (PDI), zeta potential (ξ), pH and encapsulation efficiency (EE%). The determination of the minimum biofilm inhibitory concentration (MBIC) and minimum biofilm eradication concentration (MBEC) of TOB and TOB-ZNP against K25 A2, K26 A2, K29 A2 and K31 A2 strains was performed by the crystal violet method. 

Resultados e Conclusão

The TOB-ZNP presented Ø of 202.1 nm, PDI of 0.086, ξ of -36.7±0.4 mV, pH 7.2 and EE% was 83.93%. The MBIC of TOB and TOB-ZNP were 12.5 and 0.195 µg/mL, 12.5 and 0.39 µg/mL, 6.25 and 0.195 µg/mL, and 6.25 and 0.39 µg/mL for K25 A2, K26 A2, K29 A2 and K31 A2, respectively. The MBEC of TOB and TOB-ZNP were 400 and 12.5 µg/mL, 200 and 25 µg/mL, 800 and 12.5 µg/mL, and 400 and 12,5 µg/mL for K25 A2, K26 A2, K29 A2 and K31 A2, respectively. Tobramycin encapsulated into zein nanoparticles has greater antibiofilm potential, making it a promising nanobiotechnological alternative for the development of a pharmaceutical product focused on the treatment of infections caused by resistant and biofilm-producing K. pneumoniae strains.

Palavras Chave

bacterial resistance; biofilm; nanostructures; polymeric nanoparticles.